201940-08-1

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 5-bromoisoindoline-2-carboxylate is used as a synthetic intermediate for the preparation of Isothiazoloquinolones, which exhibit enhanced antistaphylococcal activities against multidrug-resistant strains of Staphylococcus aureus. These Isothiazoloquinolones have the potential to combat antibiotic-resistant bacterial infections, addressing a significant global health concern.
Additionally, tert-Butyl 5-bromoisoindoline-2-carboxylate is used as a precursor in the synthesis of substituted isoindolines, which act as inhibitors of dipeptidyl peptidase 8/9 (DPP8/9). DPP8/9 inhibitors are of interest in the development of treatments for various diseases, including type 2 diabetes and neurodegenerative disorders, due to their role in regulating peptide processing and inflammation.

InChI:InChI=1/C13H16BrNO2/c1-13(2,3)17-12(16)15-7-9-4-5-11(14)6-10(9)8-15/h4-6H,7-8H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 127168-84-7 5-bromoisoindoline 
• 6941-75-9 5-Bromoisoindoline-1,3-dione 
• 86-90-8 4-bromophthalic anhydride 
• 39982-01-9 tert-Butoxycarbonylpivalat 
• 919346-89-7 5-bromo-2,3-dihydro-1H-isoindole hydrochloride 

Downstream Products

• 368441-44-5 2-(tert-butyl) 5-methyl isoindoline-2,5-dicarboxylate 
• 1613147-74-2 (R)-tert-butyl 5-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)isoindoline-2-carboxylate 
• 850877-60-0 C₁₅H₁₉NO₃ 
• 226070-47-9 tert-butyl 5-hydroxyisoindoline-2-carboxylate 
• 263888-56-8 tert-butyl 5-cyanoisoindoline-2-carboxylate 
• 263888-58-0 5-cyano-2,3-dihydro-1H-isoindole 
• 1415929-11-1 tert-butyl 5-(benzylthio)isoindoline-2-carboxylate 

Relevant academic research and scientific papers

APPLICATION OF MONOCYCLIC BETA-LACTAM COMPOUND IN PHARMACY

An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT

The present application relates a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the

2-Amino-2,3-dihydro-1 H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy

A series of 2-amino-2,3-dihydro-1H-indene-5-carboxamides were designed and synthesized as new selective discoidin domain receptor 1 (DDR1) inhibitors. One of the representative compounds, 7f, bound with DDR1 with a Kd value of 5.9 nM and suppre

GPR40 receptor stimulant, and preparation method, pharmaceutical composition and application thereof

The invention discloses a GPR40 receptor stimulant, and a preparation method, a pharmaceutical composition and application thereof. The invention particularly discloses a GPR40 receptor stimulant shown in general formula (I) and pharmacologically acceptable salt thereof, a preparation process of the compound, a pharmaceutical composition containing the compound of general formula (I), and application of the compound and the pharmaceutical composition in anti-diabetes.

THIAZOLE DERIVATIVE AND APPLICATIONS THEREOF

Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.

Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings

A novel series of GPR40 agonists is designed by introducing nitrogen-containing heterocyclic ring at the terminal phenyl ring of TAK-875 with the aim of decreasing its lipophilicity. Three different β-substituted phenylpropionic acids were investigated as the acidic components. A total of 34 compounds have been synthesized, among which, compound 30 exhibited comparable GPR40 agonistic activity in vitro with TAK-875 and relatively lower lipophilicity through calculation (30, EC50 = 1.2 μM, cLogP = 1.3; TAK-875: EC50 = 5.1 μM, cLogP = 3.4). Moreover, compound 30 was able to enhance the insulin secretion of primary islets isolated from normal ICR mice and showed no obvious inhibition against cytochromes P450 in vitro. In vivo, compound 30 exhibited efficacy in oral glucose tolerance test (oGTT) in normal ICR mice.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.